CLVS
-
x
x
bid
ask
09:49 PM
Bearish
48
Bullish
102
sentiment
0.00
day range
0.00
0.00
52 week range
0.00
Profile
...
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-11-09 | 2022-09 | -0.42 | N/A | N/A | N/A |
2022-08-08 | 2022-06 | -0.42 | N/A | N/A | N/A |
2022-05-04 | 2022-03 | -0.43 | N/A | N/A | N/A |
2022-02-23 | 2021-12 | -0.6 | N/A | N/A | N/A |
2021-11-03 | 2021-09 | -0.48 | N/A | N/A | N/A |
2021-08-04 | 2021-06 | -0.57 | N/A | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-11-10 | JP Morgan | Downgrade | Neutral | Underweight |
2022-05-06 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2022-05-05 | HC Wainwright & Co. | Upgrade | Buy | |
2021-09-21 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-05 | HC Wainwright & Co. | Upgrade | Buy | |
2021-05-05 | HC Wainwright & Co. | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-11-01 | GROSS PAUL EDWARD | General Counsel | 98.33K | Sale |
2022-11-01 | HARDING THOMAS C | Officer | 0.00 | Sale |
2022-11-01 | IVERS-READ GILLIAN C | Officer | 293.61K | Sale |
2022-11-01 | MUEHL DANIEL W | Chief Financial Officer | 104.83K | Sale |
2022-11-01 | ROLFE LINDSEY | Officer | 113.69K | Sale |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Group, Inc. (The) | 10.21M | 828.77K | 7.04% |
2022-09-29 | Palo Alto Investors Lp | 4.47M | 363.29K | 3.09% |
2022-09-29 | Blackrock Inc. | 4.04M | 327.67K | 2.78% |
2022-09-29 | QVT Financial LP | 3.53M | 286.23K | 2.43% |
2022-09-29 | Renaissance Technologies, LLC | 2.21M | 179.43K | 1.52% |
2022-09-29 | Geode Capital Management, LLC | 1.38M | 112.30K | 0.95% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Total Stock Market Index Fund | 4.34M | 352.67K | 3.00% |
2022-09-29 | Vanguard Extended Market Index Fund | 1.92M | 155.70K | 1.32% |
2022-09-29 | Vanguard Strategic Equity Fund | 1.68M | 136.34K | 1.16% |
2022-07-30 | Vanguard Explorer Fund, Inc. | 1.44M | 116.87K | 0.99% |
2022-11-29 | iShares NASDAQ Biotechnology ETF | 1.17M | 94.72K | 0.80% |
2022-10-30 | Fidelity Extended Market Index Fund | 747.38K | 60.69K | 0.52% |
This topic has been deleted. Only users with topic management privileges can see it.
-
IN (03) Days ABOVE 13.60. SURE
-
CLVS?? Maybe Up.... When?
-
I don’t know what’s going on with Share!!! Target $19.... When. ??
-
Shorts,you’ve been manipulated by the big boys they dropped the price set the trap and you fell for it ,they’re going to take you to the cleaners,that’s how they play —-dirty
-
-
Squeeze them shorts
-
$4 mark !!!!!!
-
Could you recommend a website where you read press releases or with reliable information about this industry?
-
Pre market tease going up
-
You know what happens when you come naked (fucked)
-
Thank you shorty
-
Shorts keep on shorting if you’re mad at yourselfs
-
Naked shorts are screwd
-
Putting the dots on BO
-
Where are the shorts ? Sweet dreams
-
Isn’t S8 so the co can grant shares or options for employees
-